Testosterone MD-Lotion Residual Washing Study

A Healthy Volunteer, Single Dose Phase I Trial to Determine the Amount of Testerone MD-Lotion 2% Remaining on the Axilla After Washing.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00996151

Acronym

MTE11

Enrollment

Registered

2009-10-16

Start date

2009-12-31

Completion date

2010-02-28

Last updated

2010-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypergonadism

Keywords

Hypergonadism, Testosterone Transfer

Brief summary

The study will evaluate the amount of Testosteron MD-Lotion 2% remaining on the axilla after a single dose application in healthy males who undergo a post dose washing procedure.

Interventions

DRUGTestosterone MD-Lotion

Single dose Testosterone MD-Lotion 2%

Study design

Allocation

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy male subjects ≥18 and ≤ 70 years

Exclusion criteria

* Disqualifying concurrent condition or allergy/sensitivity to Testosterone MD-Lotion

Design outcomes

Primary

Measure	Time frame
The amount of Testerone MD-Lotion 2% remaining on the axilla after a single dose application in healthy males who undergo a post dose washing procedure.	March 2010

Secondary

Measure	Time frame
The safety and tolerability of Testosterone MD-Lotion 2% following a single dose application. This will be performed by review of adverse events, EKG and assessment of laboratory parameters (haematology, biochemistry, urinalysis and hormone levels).	March 2010

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026